



1FW

Attorney Docket No.: 1300-1-015PCT/US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Nicola Anne Burgess  
SERIAL NO.: 10/575,311 EXAMINER: unassigned  
DATE FILED: April 11, 2006 ART UNIT: unassigned  
FOR: A PROTEIN INVOLVED IN OVARIAN CANCER

**CERTIFICATE OF MAILING UNDER 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on July 18, 2006.

Carolyn Di Meglio  
(Name of depositor)

Carolyn Di Meglio 7/18/06  
(Signature and Date)

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.


Enclosed please find copies of References CA through CC listed on the attached Form PTO-1449. However, with respect to References AA through BB, please note that due to the size of the references, a compact disc containing these references saved as Adobe PDFs is enclosed in place of a printed copy. No fee is believed due for the filing of this statement

Serial No.: 10/575,311

Attorney Docket No.: 1300-1-015PCT/US

inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.


Respectfully submitted,

A handwritten signature in cursive script, reading "Sarah J. Fashena", written over a horizontal line.

Sarah J. Fashena, Ph.D.  
Agent for Applicants  
Registration No. 57,600

KLAUBER & JACKSON LLC  
411 Hackensack Avenue  
Hackensack, New Jersey 07601  
201-487-5800

Date: July 18, 2006



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1300-1-015PCT/US
	SERIAL NO.	10/575,311
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT  (Use several sheets if necessary)	APPLICANT	Nicola Anne Burgess
	FILING DATE	April 11, 2006
	GROUP	Not yet assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	2002/0142003 A1	10/3/02	Schweifer et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	BA	WO 02/070539 A2	09/12/02	PCT			
	BB	WO 02/04508 A1	01/17/02	PCT			

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	T. Conze et al., CDCP1 Is a Novel Marker for Hematopoietic Stem Cells, Annals New York Academy of Sciences, 996:222-226 (2003)
	CB	M. Scherl-Mostageer et al., Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer, Oncogene, 20:4402-4408 (2001)
	CC	J.D. Hooper et al., Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen, Oncogene, 22:1783-1794 (2003)

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	